Schematic representation of histone-modifying factor recruitment on cccDNA minichromosomes in relation to viral protein HBx. GA, UNITED STA ...

By targeting these pathways, we can develop therapies that not only suppress viral replication but also offer a functional cure for chronic hepatitis B," he said. The implications of this review ...

Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...

Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 - - Commenced Phase 1 ELIMINATE-B ...

There are now a number of other drugs in the same class in different stages of development, which have been shown to be even more potent inhibitors of hepatitis B replication. The large experience ...

Hepatitis B virus (HBV) infection is associated with liver diseases, including chronic hepatitis, which notably increases the risk of cirrhosis and hepatocellular carcinoma (HCC) development. Although ...

Fintel reports that on March 25, 2025, Guggenheim initiated coverage of Assembly Biosciences (NasdaqGS:ASMB) with a Buy ...

Antiviral treatments strive to block a virus or halt its replication ... 2024 — A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective ...

The company’s pipeline, which includes programs in chronic hepatitis B (PBGENE-HBV), muscle dystrophy ... genetic information to support viral replication. More importantly, those patients ...

It is also developing its own therapies for respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and chronic hepatitis B virus (HBV), and started work on COVID-19 early in in the ...